Metoclopramide and tardive dyskinesia: FDA adds boxed warning

The FDA issued a press release (dated February 26, 2009) in which they announce that the agency will require Metoclopramide (Maxolon, Reglan, Degan, Maxeran, Primperan, and Pylomid) manufacturers to include a boxed warning about the risk of long term or high dose use: The U.S. Food and Drug Administration announced today that manufacturers of metoclopramide, […]

Zonisamide (Zonegran): FDA warns about risk of metabolic acidosis and issues recommendations

The FDA issued an alert (February 23, 2009) about the risk of metabolic acidosis in patients treated with zonisamide (Zonegran). An excerpt from the alert on this anticonvulsant adverse effect: Following a review of updated clinical data,  the FDA has determined that treatment with zonisamide can cause metabolic acidosis in some patients.  Zonisamide is indicated […]

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos